Eli Lilly and Company (NYSE:LLY) Shares Down 1.1% – Here’s What Happened

Eli Lilly and Company (NYSE:LLY)’s stock price traded down 1.1% during trading on Monday . The stock traded as low as $1,183.34 and last traded at $1,200.89. Approximately 2,315,010 shares traded hands during trading, a decline of 28% from the average session volume of 3,231,220 shares. The stock had previously closed at $1,213.91.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Royal Bank of Canada raised its price target on Eli Lilly to $1,500 from $1,250 and reiterated an outperform view, adding to a wave of bullish analyst calls that suggest Wall Street still sees upside in the stock. Benzinga report on RBC price target increase
• Positive Sentiment: Investors remain focused on Lilly’s GLP-1 and obesity pipeline, including strong demand for Mounjaro and Zepbound, which continues to support expectations for powerful revenue growth. 24/7 Wall St article on GLP-1 opportunity
• Positive Sentiment: TipRanks reported that Lilly’s eczema treatment was approved in Canada, reinforcing that the company has growth drivers beyond weight-loss drugs. TipRanks article on Canada approval
• Neutral Sentiment: Several recent commentary pieces question whether Eli Lilly is becoming too expensive after its huge run-up, which may temper enthusiasm even as the long-term growth story stays intact. Motley Fool article on valuation
• Neutral Sentiment: A broader late-day pullback in healthcare stocks also weighed on sentiment across the sector, including LLY. Yahoo Finance sector update
• Negative Sentiment: Tampa General has sued Eli Lilly over pulled 340B discounts, creating a legal and regulatory overhang that could add pressure if the dispute broadens. Becker’s Hospital Review article on lawsuit

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Truist Financial lifted their price target on Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the stock a “buy” rating in a research note on Wednesday. Barclays increased their price objective on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a research note on Monday, May 4th. Guggenheim reaffirmed a “buy” rating and set a $1,183.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, May 5th. UBS Group reaffirmed a “buy” rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. Finally, Morgan Stanley increased their target price on shares of Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the company an “overweight” rating in a research report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $1,255.89.

Eli Lilly and Company Trading Down 1.4%

The company has a market capitalization of $1.15 trillion, a PE ratio of 43.30, a PEG ratio of 1.49 and a beta of 0.51. The company has a fifty day simple moving average of $1,078.08 and a 200-day simple moving average of $1,030.27. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts predict that Eli Lilly and Company will post 35.74 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is 24.58%.

Institutional Trading of Eli Lilly and Company

Several hedge funds have recently made changes to their positions in LLY. Brighton Jones LLC lifted its position in Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after buying an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC boosted its stake in shares of Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares during the period. Schnieders Capital Management LLC. lifted its holdings in Eli Lilly and Company by 16.7% during the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock worth $6,231,000 after buying an additional 1,141 shares in the last quarter. Flow Traders U.S. LLC purchased a new position in Eli Lilly and Company in the 2nd quarter valued at approximately $356,000. Finally, Nebula Research & Development LLC acquired a new position in shares of Eli Lilly and Company in the second quarter worth $749,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.